AZN Jan 2025 100.000 put
| Previous Close | 20.65 |
| Open | 20.65 |
| Bid | 17.90 |
| Ask | 20.80 |
| Strike | 100.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 20.65 - 20.65 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1 |
ZacksZacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer
Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.
Zacks5 Large Drug Stocks to Watch From a Thriving Industry
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are worth retaining in one's portfolio.
Business WireAIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
WILMINGTON, Del., October 07, 2024--Positive high-level results from the BATURA Phase IIIb trial showed AstraZeneca’s AIRSUPRA ® (albuterol/budesonide) met the primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms compared to as-needed albuterol.1 The trial included patients with intermittent or mild persistent asthma, including those on short-acting
